Back to results
US 2020/0138927 A1Published application
Non-cross-linked acellular pertussis antigens for use in combination vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorsLorenzo TARLI, Mario CONTORNI, Alessandro BARTALESI
Life of this patent
Estimating the term…
Abstract
The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed.
Claims2
A process for preparing an aP component, comprising:
- a. growing a culture of a B. pertussis strain expressing a genetically detoxified pertussis toxin;
- b. purifying two or more B. pertussis antigens from the culture to obtain two or more batches each containing a different purified B. pertussis antigen;
- and
- c. mixing the two or more batches to prepare the aP component,
- wherein the process is characterised in that the purified B. pertussis antigens are not treated with a cross-linking agent, and
- wherein the aP component comprises at least two non-cross-linked B. pertussis antigens selected from PT, FHA and pertactin with the proviso that any PT is genetically detoxified.
3 more elements
Dependencies are inferred from the claim text.